Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel Free SPEC Stock Alerts

Spectaire (SPEC) Competitors

Spectaire logo
$0.0005 0.00 (0.00%)
As of 07/24/2026
Compare

SPEC vs. TBIO, THMO, HTGMQ, PRENW, and SMAPW

Should you buy Spectaire stock or one of its competitors? MarketBeat compares Spectaire with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Spectaire include Telesis Bio (TBIO), ThermoGenesis (THMO), HTG Molecular Diagnostics (HTGMQ), Prenetics Global (PRENW), and SportsMap Tech Acquisition (SMAPW). These companies are all part of the "measuring and control equipment" industry.

How does Spectaire compare to Telesis Bio?

Spectaire (NASDAQ:SPEC) and Telesis Bio (NASDAQ:TBIO) are both small-cap measuring and control equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

Spectaire has a beta of -6.25, suggesting that its share price is 725% less volatile than the broader market. Comparatively, Telesis Bio has a beta of 2.43, suggesting that its share price is 143% more volatile than the broader market.

26.5% of Spectaire shares are owned by institutional investors. Comparatively, 37.6% of Telesis Bio shares are owned by institutional investors. 25.4% of Spectaire shares are owned by company insiders. Comparatively, 24.5% of Telesis Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Spectaire has higher earnings, but lower revenue than Telesis Bio. Spectaire is trading at a lower price-to-earnings ratio than Telesis Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SpectaireN/AN/A$8.95M-$0.30N/A
Telesis Bio$225.09M0.00-$47.72M-$20.52N/A

Spectaire has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%. Telesis Bio's return on equity of 0.00% beat Spectaire's return on equity.

Company Net Margins Return on Equity Return on Assets
SpectaireN/A -81.22% 304.57%
Telesis Bio -336.59%N/A -61.89%

In the previous week, Spectaire's average media sentiment score of 0.00 equaled Telesis Bio'saverage media sentiment score.

Company Overall Sentiment
Spectaire Neutral
Telesis Bio Neutral

Summary

Spectaire and Telesis Bio tied by winning 5 of the 10 factors compared between the two stocks.

How does Spectaire compare to ThermoGenesis?

Spectaire (NASDAQ:SPEC) and ThermoGenesis (NASDAQ:THMO) are both small-cap measuring and control equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

Spectaire has a beta of -6.25, indicating that its stock price is 725% less volatile than the broader market. Comparatively, ThermoGenesis has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market.

ThermoGenesis' return on equity of 0.00% beat Spectaire's return on equity.

Company Net Margins Return on Equity Return on Assets
SpectaireN/A -81.22% 304.57%
ThermoGenesis N/A N/A N/A

Spectaire has higher earnings, but lower revenue than ThermoGenesis. Spectaire is trading at a lower price-to-earnings ratio than ThermoGenesis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SpectaireN/AN/A$8.95M-$0.30N/A
ThermoGenesis$9.61M0.00-$17.98M-$5.14N/A

In the previous week, Spectaire's average media sentiment score of 0.00 equaled ThermoGenesis'average media sentiment score.

Company Overall Sentiment
Spectaire Neutral
ThermoGenesis Neutral

26.5% of Spectaire shares are held by institutional investors. Comparatively, 5.8% of ThermoGenesis shares are held by institutional investors. 25.4% of Spectaire shares are held by insiders. Comparatively, 78.0% of ThermoGenesis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

ThermoGenesis beats Spectaire on 5 of the 9 factors compared between the two stocks.

How does Spectaire compare to HTG Molecular Diagnostics?

HTG Molecular Diagnostics (NASDAQ:HTGMQ) and Spectaire (NASDAQ:SPEC) are both measuring and control equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

HTG Molecular Diagnostics' return on equity of 0.00% beat Spectaire's return on equity.

Company Net Margins Return on Equity Return on Assets
HTG Molecular DiagnosticsN/A N/A N/A
Spectaire N/A -81.22%304.57%

In the previous week, HTG Molecular Diagnostics' average media sentiment score of 0.00 equaled Spectaire'saverage media sentiment score.

Company Overall Sentiment
HTG Molecular Diagnostics Neutral
Spectaire Neutral

Spectaire has lower revenue, but higher earnings than HTG Molecular Diagnostics. Spectaire is trading at a lower price-to-earnings ratio than HTG Molecular Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HTG Molecular Diagnostics$6.37M0.00-$21.59M-$2.28N/A
SpectaireN/AN/A$8.95M-$0.30N/A

HTG Molecular Diagnostics has a beta of 3.06, meaning that its share price is 206% more volatile than the broader market. Comparatively, Spectaire has a beta of -6.25, meaning that its share price is 725% less volatile than the broader market.

26.5% of Spectaire shares are held by institutional investors. 2.6% of HTG Molecular Diagnostics shares are held by insiders. Comparatively, 25.4% of Spectaire shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Spectaire beats HTG Molecular Diagnostics on 5 of the 9 factors compared between the two stocks.

How does Spectaire compare to Prenetics Global?

Prenetics Global (NASDAQ:PRENW) and Spectaire (NASDAQ:SPEC) are both measuring and control equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

26.5% of Spectaire shares are held by institutional investors. 25.4% of Spectaire shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Spectaire has lower revenue, but higher earnings than Prenetics Global.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prenetics Global$120.07MN/AN/AN/AN/A
SpectaireN/AN/A$8.95M-$0.30N/A

Prenetics Global's return on equity of 0.00% beat Spectaire's return on equity.

Company Net Margins Return on Equity Return on Assets
Prenetics GlobalN/A N/A N/A
Spectaire N/A -81.22%304.57%

In the previous week, Prenetics Global had 2 more articles in the media than Spectaire. MarketBeat recorded 2 mentions for Prenetics Global and 0 mentions for Spectaire. Prenetics Global's average media sentiment score of 0.43 beat Spectaire's score of 0.00 indicating that Prenetics Global is being referred to more favorably in the media.

Company Overall Sentiment
Prenetics Global Neutral
Spectaire Neutral

Summary

Prenetics Global beats Spectaire on 4 of the 7 factors compared between the two stocks.

How does Spectaire compare to SportsMap Tech Acquisition?

Spectaire (NASDAQ:SPEC) and SportsMap Tech Acquisition (NASDAQ:SMAPW) are both measuring and control equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SpectaireN/AN/A$8.95M-$0.30N/A
SportsMap Tech AcquisitionN/AN/AN/AN/AN/A

SportsMap Tech Acquisition's return on equity of 0.00% beat Spectaire's return on equity.

Company Net Margins Return on Equity Return on Assets
SpectaireN/A -81.22% 304.57%
SportsMap Tech Acquisition N/A N/A N/A

26.5% of Spectaire shares are held by institutional investors. 25.4% of Spectaire shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Spectaire's average media sentiment score of 0.00 equaled SportsMap Tech Acquisition'saverage media sentiment score.

Company Overall Sentiment
Spectaire Neutral
SportsMap Tech Acquisition Neutral

Summary

Spectaire beats SportsMap Tech Acquisition on 3 of the 4 factors compared between the two stocks.

Get Spectaire News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPEC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPEC vs. The Competition

Export
MetricSpectaireMeasuring & controlling devices IndustryComputer SectorNASDAQ Exchange
Market Cap$9K$95.06M$37.12B$12.20B
Dividend YieldN/A10.83%3.17%9.41%
P/E Ratio0.006.26167.8923.63
Price / SalesN/A8.80596.19111.98
Price / CashN/A8.3843.4058.78
Price / Book0.001.339.076.01
Net Income$8.95M$7.16M$1.07B$331.99M
7 Day PerformanceN/A0.74%-1.81%-0.63%
1 Month PerformanceN/A1.98%-3.68%-3.04%
1 Year PerformanceN/A143.47%133.84%13.30%

Spectaire Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPEC
Spectaire
N/A$0.00
flat		N/AN/A$9KN/AN/A8
TBIO
Telesis Bio
N/A$0.01
flat		N/AN/A$18K$225.09MN/A200
THMO
ThermoGenesis
N/AN/AN/AN/A$1K$9.61MN/A40
HTGMQ
HTG Molecular Diagnostics
N/AN/AN/AN/A$0.00$6.37MN/A90
PRENW
Prenetics Global
N/A$0.02
+14.3%		N/A-64.7%$0.00$120.07MN/A1

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SPEC) was last updated on 7/26/2026 by MarketBeat.com Staff.
From Our Partners
Universal basic income is not impossible. It exist (kind of)
Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...
Freedom Financial | Sponsoredtc pixel
Oxford Club Analyst’s Urgent AI Warning
Alexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...
The Oxford Club | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
This tiny piece of glass could be bigger than GPUs
Jensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...
Brownstone Research | Sponsoredtc pixel
The 90%-off options that empty accounts
A call that cost $3.00 last month now trades for $0.30 - a 90% discount that looks tempting. It's not a bar...
Profits Run | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel